---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-035798"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2026-05-18T11:06:12+00:00"
generated_at: "2026-05-18T11:13:03.316384+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft

## Summary
- Net purchase price of $135M funded via $150M delayed draw term loan.
- Contingent consideration up to $200M based on Nexus product performance, payable ~2 years post-close.
- FDA approved Premarket Approval for Nexus branched endovascular stent graft system in April 2026.
- Acquisition completes Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA devices.

## SEC filing metadata
- accession: 0001628280-26-035798
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2026-05-18T11:06:12+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000162828026035798/0001628280-26-035798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000162828026035798/aort-20260518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-035798
- JSON: https://secwatch.observer/filing/0001628280-26-035798.json
- Plain text: https://secwatch.observer/filing/0001628280-26-035798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.